

## **Global Gastrointestinal OTC Drugs Market Report and Forecast 2024-2032**

Market Report (7 days) | 2024-02-07 | 160 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

### **Report description:**

Global Gastrointestinal OTC Drugs Market Report and Forecast 2024-2032

Global Gastrointestinal OTC Drugs Market Outlook

The global gastrointestinal OTC Drugs market size was valued at USD 41.96 billion in 2023, driven by Innovation in drug formulations and delivery systems across the globe. The market size is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 to achieve a value of USD 64.5 billion by 2032.

Gastrointestinal OTC Drugs: Introduction

Gastrointestinal (GI) OTC drugs are medications available without a prescription, used to treat common digestive issues like heartburn, indigestion, constipation, and diarrhea. These include antacids, proton pump inhibitors, laxatives, and anti-diarrheal agents. They offer convenience and quick relief for minor discomforts but are not meant for long-term or serious conditions. It's important to use them as directed and consult a healthcare professional if symptoms persist or worsen, to ensure safe and effective treatment.

Key Trends in the Global Gastrointestinal OTC Drugs Market

There's a growing trend of self-medication among consumers for minor GI issues, driven by the accessibility and convenience of OTC drugs. This is supported by the availability of information online, allowing consumers to make informed choices about treating common digestive complaints.

Consumers are increasingly seeking natural and organic GI products, perceiving them as safer and with fewer side effects compared to synthetic drugs. This trend is leading to a rise in the availability and popularity of herbal and natural supplements for digestive health.

Innovation in drug formulations and delivery systems, such as chewable tablets, dissolvable strips, and extended-release capsules, is improving the efficacy and convenience of GI OTC drugs. This enhances patient compliance and satisfaction, driving market growth.

There's a growing emphasis on preventive healthcare, leading consumers to use GI OTC drugs not only for treatment but also for preventive measures. Products that contribute to overall digestive health, like probiotics and dietary supplements, are gaining traction.

Regulatory bodies are increasingly scrutinizing OTC drugs to ensure consumer safety. This leads to rigorous labeling requirements

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

and consumer education initiatives about the proper use of OTC drugs and the importance of consulting healthcare professionals for persistent or serious symptoms.

The rise of e-commerce platforms is making GI OTC drugs more accessible, providing consumers with convenient purchasing options. Online pharmacies and health product websites offer a wide range of products, competitive pricing, and the added convenience of home delivery.

#### Global Gastrointestinal OTC Drugs Market Segmentation

##### Market Breakup by Class

- Antacids
- Laxatives
- Anti-Diarrheal
- Anti-Emetics
- Others

##### Market Breakup by Indication

- Heartburn
- Diarrhea
- Constipation
- Gastroesophageal Reflux Disease
- Others

##### Market Breakup by End User

- Hospitals
- Clinics
- Home Healthcare
- Others

##### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Global Gastrointestinal OTC Drugs Market Overview

In North America, the market for gastrointestinal OTC drugs is robust, driven by a culture of self-medication and a high prevalence of digestive disorders related to lifestyle and dietary habits. The U.S. is a significant market, with a wide range of available products and strong consumer trust in OTC solutions for immediate relief. There's also a growing trend towards natural and organic digestive remedies, reflecting the broader shift towards health and wellness in the region.

Europe's market is characterized by strong regulatory frameworks ensuring the safety and efficacy of OTC drugs. Consumer preference for OTC solutions for minor gastrointestinal issues is high, and there's a growing demand for products with natural ingredients. The market is also influenced by public health initiatives promoting responsible self-medication and the prudent use of OTC drugs, alongside a focus on preventive healthcare and dietary management to reduce the incidence of digestive issues. The market in the Asia-Pacific region is expanding rapidly, driven by increasing consumer awareness and improving access to healthcare products. Urbanization, changing lifestyles, and dietary shifts contribute to the prevalence of gastrointestinal issues, fueling the demand for OTC remedies. However, the market is diverse, with variations in consumer preferences and regulatory landscapes. Traditional herbal and natural remedies remain popular in many countries, alongside a growing acceptance of Western OTC gastrointestinal drugs.

#### Global Gastrointestinal OTC Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- []Mylan N.V.
- []Sandoz AG
- []Johnson & Johnson Services
- []Sun Pharmaceuticals Industries
- []Teva Pharmaceuticals Industries
- []Zydus Cadila
- []Sanofi
- []Bayer AG
- []Pfizer Inc.
- []Amneal Pharmaceutical Inc.
- []Procter & Gamble
- []Hikma Pharmaceutical PLC
- []Perrigo Pharmaceutical Plc.
- []Abbott
- []Lupin

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

## Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Gastrointestinal OTC Drugs Market Overview
  - 3.1 Global Gastrointestinal OTC Drugs Market Historical Value (2017-2023)
  - 3.2 Global Gastrointestinal OTC Drugs Market Forecast Value (2024-2032)
- 4 Global Gastrointestinal OTC Drugs Market Landscape
  - 4.1 Global Gastrointestinal OTC Drugs Market: Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Gastrointestinal OTC Drugs Market: Product Landscape
    - 4.2.1 Analysis by Type
    - 4.2.2 Analysis by Technology
    - 4.2.3 Analysis by Applications
- 5 Global Gastrointestinal OTC Drugs Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model
  - 5.4 Key Demand Indicators
  - 5.5 Key Price Indicators
  - 5.6 Industry Events, Initiatives, and Trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.7 Value Chain Analysis
- 6 Global Gastrointestinal OTC Drugs Market Segmentation
  - 6.1 Global Gastrointestinal OTC Drugs Market by Class
    - 6.1.1 Market Overview
    - 6.1.2 Antacids
    - 6.1.3 Anti-Diarrheal
    - 6.1.4 Anti-Emetics
    - 6.1.5 Laxatives
    - 6.1.6 Others
  - 6.2 Global Gastrointestinal OTC Drugs Market by Indication
    - 6.2.1 Market Overview
    - 6.2.2 Heartburn
    - 6.2.3 Diarrhea
    - 6.2.4 Constipation
    - 6.2.5 Gastroesophageal Reflux Disease
    - 6.2.6 Others
  - 6.3 Global Gastrointestinal OTC Drugs Market by End User
    - 6.3.1 Market Overview
    - 6.3.2 Hospitals
    - 6.3.3 Clinics
    - 6.3.4 Home Healthcare
    - 6.3.5 Others
  - 6.4 Global Gastrointestinal OTC Drugs Market by Region
    - 6.4.1 Market Overview
    - 6.4.2 North America
    - 6.4.3 Europe
    - 6.4.4 Asia Pacific
    - 6.4.5 Latin America
    - 6.4.6 Middle East and Africa
- 7 North America Gastrointestinal OTC Drugs Market
  - 7.1 Market Share by Country
  - 7.2 United States of America
  - 7.3 Canada
- 8 Europe Gastrointestinal OTC Drugs Market
  - 8.1 Market Share by Country
  - 8.2 United Kingdom
  - 8.3 Germany
  - 8.4 France
  - 8.5 Italy
  - 8.6 Others
- 9 Asia Pacific Gastrointestinal OTC Drugs Market
  - 9.1 Market Share by Country
  - 9.2 China
  - 9.3 Japan
  - 9.4 India
  - 9.5 ASEAN
  - 9.6 Australia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.7 Others
- 10 Latin America Gastrointestinal OTC Drugs Market
  - 10.1 Market Share by Country
  - 10.2 Brazil
  - 10.3 Argentina
  - 10.4 Mexico
  - 10.5 Others
- 11 Middle East and Africa Gastrointestinal OTC Drugs Market
  - 11.1 Market Share by Country
  - 11.2 Saudi Arabia
  - 11.3 United Arab Emirates
  - 11.4 Nigeria
  - 11.5 South Africa
  - 11.6 Other
- 12 Regulatory Framework
  - 12.1 Regulatory Overview
    - 12.1.1 US FDA
    - 12.1.2 EU EMA
    - 12.1.3 INDIA CDSCO
    - 12.1.4 JAPAN PMDA
    - 12.1.5 Others
- 13 Patent Analysis
  - 13.1 Analysis by Type of Patent
  - 13.2 Analysis by Publication year
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Patent Age
  - 13.5 Analysis by CPC Analysis
  - 13.6 Analysis by Patent Valuation
  - 13.7 Analysis by Key Players
- 14 Grants Analysis
  - 14.1 Analysis by year
  - 14.2 Analysis by Amount Awarded
  - 14.3 Analysis by Issuing Authority
  - 14.4 Analysis by Grant Application
  - 14.5 Analysis by Funding Institute
  - 14.6 Analysis by NIH Departments
  - 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
  - 15.1 Analysis by Trial Registration Year
  - 15.2 Analysis by Trial Status
  - 15.3 Analysis by Trial Phase
  - 15.4 Analysis by Therapeutic Area
  - 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
  - 16.1 Analysis by Funding Instances
  - 16.2 Analysis by Type of Funding
  - 16.3 Analysis by Funding Amount

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
  - 17.1 Analysis by Partnership Instances
  - 17.2 Analysis by Type of Partnership
  - 17.3 Analysis by Leading Players
  - 17.4 Analysis by Geography
- 18 Supplier Landscape
  - 18.1 Mylan N.V.
    - 18.1.1 Financial Analysis
    - 18.1.2 Product Portfolio
    - 18.1.3 Demographic Reach and Achievements
    - 18.1.4 Mergers and Acquisitions
    - 18.1.5 Certifications
  - 18.2 Sandoz AG
    - 18.2.1 Financial Analysis
    - 18.2.2 Product Portfolio
    - 18.2.3 Demographic Reach and Achievements
    - 18.2.4 Mergers and Acquisitions
    - 18.2.5 Certifications
  - 18.3 Johnson & Johnson Services
    - 18.3.1 Financial Analysis
    - 18.3.2 Product Portfolio
    - 18.3.3 Demographic Reach and Achievements
    - 18.3.4 Mergers and Acquisitions
    - 18.3.5 Certifications
  - 18.4 Sun Pharmaceuticals Industries
    - 18.4.1 Financial Analysis
    - 18.4.2 Product Portfolio
    - 18.4.3 Demographic Reach and Achievements
    - 18.4.4 Mergers and Acquisitions
    - 18.4.5 Certifications
  - 18.5 Teva Pharmaceuticals Industries
    - 18.5.1 Financial Analysis
    - 18.5.2 Product Portfolio
    - 18.5.3 Demographic Reach and Achievements
    - 18.5.4 Mergers and Acquisitions
    - 18.5.5 Certifications
  - 18.6 Zydus Cadila
    - 18.6.1 Financial Analysis
    - 18.6.2 Product Portfolio
    - 18.6.3 Demographic Reach and Achievements
    - 18.6.4 Mergers and Acquisitions
    - 18.6.5 Certifications
  - 18.7 Sanofi
    - 18.7.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 Bayer AG
  - 18.8.1 Financial Analysis
  - 18.8.2 Product Portfolio
  - 18.8.3 Demographic Reach and Achievements
  - 18.8.4 Mergers and Acquisitions
  - 18.8.5 Certifications
- 18.9 Pfizer Inc.
  - 18.9.1 Financial Analysis
  - 18.9.2 Product Portfolio
  - 18.9.3 Demographic Reach and Achievements
  - 18.9.4 Mergers and Acquisitions
  - 18.9.5 Certifications
- 18.10 Amneal Pharmaceutical Inc.
  - 18.10.1 Financial Analysis
  - 18.10.2 Product Portfolio
  - 18.10.3 Demographic Reach and Achievements
  - 18.10.4 Mergers and Acquisitions
  - 18.10.5 Certifications
- 18.11 Procter & Gamble
  - 18.11.1 Financial Analysis
  - 18.11.2 Product Portfolio
  - 18.11.3 Demographic Reach and Achievements
  - 18.11.4 Mergers and Acquisitions
  - 18.11.5 Certifications
- 18.12 Hikma Pharmaceutical PLC
  - 18.12.1 Financial Analysis
  - 18.12.2 Product Portfolio
  - 18.12.3 Demographic Reach and Achievements
  - 18.12.4 Mergers and Acquisitions
  - 18.12.5 Certifications
- 18.13 Perrigo Pharmaceutical Plc.
  - 18.13.1 Financial Analysis
  - 18.13.2 Product Portfolio
  - 18.13.3 Demographic Reach and Achievements
  - 18.13.4 Mergers and Acquisitions
  - 18.13.5 Certifications
- 18.14 Abbott
  - 18.14.1 Financial Analysis
  - 18.14.2 Product Portfolio
  - 18.14.3 Demographic Reach and Achievements
  - 18.14.4 Mergers and Acquisitions
  - 18.14.5 Certifications
- 18.15 Lupin

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 18.15.1 Financial Analysis
- 18.15.2 Product Portfolio
- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Mergers and Acquisitions
- 18.15.5 Certifications
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
  - 20.1 Very Small Companies
  - 20.2 Small Companies
  - 20.3 Mid-Sized Companies
  - 20.4 Large Companies
  - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
  - 21.1 Government Funded
  - 21.2 Private Insurance
  - 21.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.



## Global Gastrointestinal OTC Drugs Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-07 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com